Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832

Watchlist Manager
Shenzhen New Industries Biomedical Engineering Co Ltd Logo
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Watchlist
Price: 60.8 CNY 0.56% Market Closed
Market Cap: 47.8B CNY
Have any thoughts about
Shenzhen New Industries Biomedical Engineering Co Ltd?
Write Note
Shenzhen New Industries Biomedical Engineering Co Ltd
/
Income Statement
/
Net Income (Common)

Shenzhen New Industries Biomedical Engineering Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen New Industries Biomedical Engineering Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Net Income (Common)
¥1.7B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Net Income (Common)
¥1.9B
CAGR 3-Years
-6%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
Net Income (Common)
¥304m
CAGR 3-Years
47%
CAGR 5-Years
72%
CAGR 10-Years
N/A
Autobio Diagnostics Co Ltd
SSE:603658
Net Income (Common)
¥1.3B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Net Income (Common)
¥580.4m
CAGR 3-Years
-47%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Intco Medical Technology Co Ltd
SZSE:300677
Net Income (Common)
¥739.6m
CAGR 3-Years
-57%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View

Market Cap
47.8B CNY
Industry
Health Care

Amidst the sprawling innovation-centric landscape of Shenzhen, Shenzhen New Industries Biomedical Engineering Co., Ltd., often abbreviated as SNIBE, stands out as a beacon in the realm of biotechnology. Founded in 1995, SNIBE has steadily carved out a significant niche in the medical devices industry, particularly in in-vitro diagnostic products. The company has become synonymous with the development, manufacture, and sale of diagnostic reagents and fully automated chemiluminescence immunoassay systems, which have gained widespread recognition in over 150 countries. By focusing on the integration of cutting-edge technology in diagnostic immunoassays, SNIBE ensures that hospitals and laboratories worldwide can attain high accuracy and efficiency in medical testing, while concurrently meeting the growing global demand for advanced diagnostic tools. The financial engine that propels SNIBE is powered by its robust supply chain and diversified product offerings. With its line-up of innovative diagnostic products, the company generates the bulk of its revenue through long-term contracts with health institutions, research centers, and clinical laboratories. These partnerships are augmented by continuous investment in research and development, ensuring a steady flow of novel products capable of addressing pressing medical needs. Additionally, SNIBE’s strategic emphasis on international markets has fortified its revenue streams, allowing it to mitigate risks associated with saturation or volatility in domestic markets. Through its unwavering focus on innovation and strategic expansion, SNIBE not only sustains its financial health but also continually contributes to advancements in global healthcare diagnostics.

Intrinsic Value
84.26 CNY
Undervaluation 28%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Shenzhen New Industries Biomedical Engineering Co Ltd's Net Income (Common)?
Net Income (Common)
1.7B CNY

Based on the financial report for Dec 31, 2023, Shenzhen New Industries Biomedical Engineering Co Ltd's Net Income (Common) amounts to 1.7B CNY.

What is Shenzhen New Industries Biomedical Engineering Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
19%

Over the last year, the Net Income (Common) growth was 25%. The average annual Net Income (Common) growth rates for Shenzhen New Industries Biomedical Engineering Co Ltd have been 21% over the past three years , 19% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 236,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.